The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgAN
Participants
Moderator: Dia Waguespack, MD, UTHealth, Houston, TX
Speaker: Chris Gisler, MD, Travere Therapeutics, Inc., Senior Medical Director
Panelists:
-
- Raymond Hsu, MD, MAS, UCSF Health, San Francisco, CA
- Zainab Obaidi, MD, University of Chicago, Chicago, IL
Objectives
In this webinar we:
- Reviewed the indication and mode of action (MoA) of sparsentan in IgA nephropathy, including recent updates to the Risk Evaluation and Mitigation Strategies (REMS) requirements
- Highlighted the efficacy and safety findings from the Phase 3 PROTECT trial, including results from a post hoc analysis of proteinuria remission
- Discussed the potential effects of sparsentan on kidney-specific inflammation and glomerular health, as assessed in animal models
- Explored efficacy, safety, and potential anti-inflammatory effects of sparsentan from the Phase 2 SPARTAN Study
- Examined the efficacy and safety of replacing renin-angiotensin system inhibitors (RASi) with sparsentan in patients concurrently on sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Browse our collection of related resources
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy (PROTECT): 2-year Results From a Randomised, Active-Controlled, Phase 3 Trial
Authors: Rovin BH, Barratt J, Heerspink HJL et al.
Type: Publication
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
Authors: Heerspink JLH, Tesar V, Komers R et al.
Type: Poster
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
Authors: Cheung CK, Moody S, Dhaun N et al.
Type: Presentation
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti-inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
Authors: Cheung CK, Barratt WA, Chaki S et al.
Type: Presentation
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
Authors: Ayoub I, Tang S, Kooienga L et al.
Type: Presentation
Sparsentan Is Superior to Losartan in the gddY Mouse Model of IgA Nephropathy
Authors: Nagasawa H, Ueda S, Suzuki H et al.
Type: Publication
MA-SP-25-0168 | November 2025